Amebiasis Intestinalis

01Pathophysiology

Intestinal amebiasis begins with the ingestion of mature cysts of Entamoeba histolytica, typically through fecally contaminated water or food. These cysts are resistant to gastric acid and pass intact into the small intestine, where excystation occurs. Each cyst releases trophozoites, the motile and invasive form of the organism, which then colonize the cecum and ascending colon as their primary site of infection.
The trophozoites adhere to the colonic epithelium using a surface protein called galactose/N-acetylgalactosamine (Gal/GalNAc) lectin. Once attached, they secrete cysteine proteases that degrade the extracellular matrix and cleave IgA, effectively evading the mucosal immune response. Additionally, trophozoites kill host epithelial cells and neutrophils through contact-dependent cytolysis, a process mediated by the release of amoebapores, which are pore-forming peptides that punch holes in cell membranes.
This enzymatic destruction and cytolysis produces the hallmark flask-shaped ulcers, where the organism burrows through the surface epithelium and undermines the mucosa laterally in the submucosa. The ulcers have a narrow neck at the mucosal surface and a wider base in the submucosa, explaining why the overlying mucosa between ulcers can appear entirely normal. This pattern of skip lesions with undermining ulceration is what distinguishes amebic colitis histologically from inflammatory bowel disease.
The destruction of the mucosal barrier and submucosal blood vessels leads to bloody, mucoid diarrhea. Trophozoites phagocytose red blood cells at the ulcer base, and this is why finding trophozoites with ingested erythrocytes on microscopy is considered pathognomonic. If the invasion reaches the portal venous system, trophozoites can disseminate hematogenously to the liver, producing an amebic liver abscess, the most common extraintestinal complication.

02Classification and Clinical Manifestation

03Diagnostic Workup

The diagnostic workup for intestinal amebiasis must accomplish two things: confirm that the patient has an amebic infection and prove that the causative organism is E. histolytica rather than the morphologically identical but non-pathogenic E. dispar. This distinction is critical because E. dispar does not cause invasive disease and does not require treatment.
Stool microscopy examining fresh or preserved specimens remains the traditional first step. The pathognomonic finding is trophozoites that have phagocytosed red blood cells. However, microscopy has significant limitations: sensitivity is only 25 to 60% with a single specimen and it cannot distinguish E. histolytica from E. dispar based on morphology alone. Collecting at least three stool samples on separate days improves yield.
In practice, the stool antigen detection test (ELISA) targeting the Gal/GalNAc lectin or E. histolytica-associated antigens is the preferred initial diagnostic step in settings where it is available. It provides rapid results and reliably differentiates E. histolytica from E. dispar, solving the key limitation of microscopy.
Stool PCR is the most accurate stool-based method. It has the highest sensitivity and provides definitive species identification. When available, PCR should be used to confirm ambiguous or borderline results.
Serology detects anti-amebic IgG antibodies and is positive in the majority of patients with invasive disease. However, antibodies can persist for years after a resolved infection, so a positive result in someone living in an endemic area does not necessarily indicate active disease. Serology is most useful when suspecting an amebic liver abscess rather than for isolated intestinal disease.
Colonoscopy is not routinely needed but becomes important when the clinical picture overlaps with inflammatory bowel disease. The endoscopic hallmark is discrete, flask-shaped ulcers with a yellowish or necrotic base and normal-appearing surrounding mucosa. Biopsies should be taken from the ulcer edge (not the necrotic base) to maximize the chance of identifying trophozoites.

04Management and Treatment

The cornerstone of treatment is understanding the two-drug approach. This concept is tested repeatedly: a tissue amebicide alone is not sufficient, and a luminal amebicide alone does not treat invasive disease. Both arms of therapy serve a distinct purpose.
Metronidazole is the tissue amebicide of choice. It is absorbed systemically and reaches therapeutic concentrations in the colonic wall and liver, where it kills invasive trophozoites. The standard dosing is 750 mg orally three times daily for 7 to 10 days. Side effects include a metallic taste, nausea, and a disulfiram-like reaction with alcohol. Tinidazole (2 g orally once daily for 3 to 5 days) is an acceptable alternative with a shorter course and better tolerability but equivalent efficacy.
The critical teaching point is that metronidazole achieves poor luminal concentrations and does not reliably eliminate cysts residing in the intestinal lumen. Without a luminal agent, up to 40 to 60% of patients will relapse from residual intraluminal cysts. This is why paromomycin must always follow the tissue agent. Paromomycin is a non-absorbable aminoglycoside that acts exclusively within the gut lumen to destroy remaining cysts. The dosing is 25 to 35 mg/kg/day divided into three doses for 7 days. An alternative luminal agent is diloxanide furoate (500 mg TID for 10 days), used primarily in regions where paromomycin is unavailable.
For asymptomatic cyst carriers, only the luminal agent is needed because there is no tissue invasion. However, treatment is still indicated to prevent progression to invasive disease and to interrupt community transmission.
In fulminant colitis, metronidazole is given intravenously, and the patient requires close monitoring for signs of perforation or toxic megacolon. Surgical intervention (subtotal colectomy) is warranted if there is free perforation, uncontrolled hemorrhage, or failure to improve within 72 to 96 hours of medical therapy.
Contraindication to note: Metronidazole should be used with caution in the first trimester of pregnancy due to potential teratogenicity. Paromomycin, being non-absorbed, is considered safer in pregnancy for treating asymptomatic carriers, but invasive disease in a pregnant patient still requires metronidazole because the risk of untreated fulminant amebiasis outweighs the drug risk.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most tested concept in intestinal amebiasis is the two-drug treatment requirement. A common trap is selecting metronidazole alone as the complete treatment. The question stem may describe a patient who improves clinically on metronidazole and then ask for the "next best step." The answer is always to prescribe a luminal agent (paromomycin) after completing the tissue amebicide. Choosing to observe or stop treatment is the intended wrong answer.
The second major pitfall involves the misdiagnosis of amebiasis as ulcerative colitis. Vignettes may present a patient with chronic bloody diarrhea and colonic ulceration who is started on corticosteroids. The patient then rapidly deteriorates with fulminant colitis and perforation. The teaching point is that corticosteroids suppress the immune response to E. histolytica, converting a contained infection into a life-threatening one. Amebiasis must always be excluded by stool testing or serology before initiating immunosuppressive therapy for suspected inflammatory bowel disease, particularly in patients with travel history to endemic regions.
A third commonly tested concept is species differentiation. The vignette may describe cysts on stool microscopy and ask whether treatment is indicated. The answer depends on whether the organism is E. histolytica or E. dispar. Since microscopy alone cannot distinguish the two, the next step is an antigen test or PCR. Treating every patient with Entamoeba cysts on microscopy without species confirmation is a distractor designed to test whether you understand this limitation.
Finally, recognize the pathognomonic finding: trophozoites containing ingested red blood cells. No other intestinal protozoan displays erythrophagocytosis. When this finding appears in a vignette, it points directly to E. histolytica and eliminates E. dispar from consideration, because only the pathogenic species invades tissue and phagocytoses erythrocytes.